Cellceutix Corp (CTIX) 1.4999 $CTIX
Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Marketwired - Mon Jun 06, 6:01AM CDT
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA" in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA.
Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Marketwired - Tue May 31, 6:00AM CDT
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed.
Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Marketwire Canada - Thu May 26, 6:01AM CDT
BEVERLY, MA--(Marketwired - May 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis.
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Marketwired - Tue May 24, 9:01AM CDT
BEVERLY, MA--(Marketwired - May 24, 2016) -
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
Marketwire Canada - Wed May 11, 8:30AM CDT
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.22 (-0.07), OCAT: 8.47 (+0.01), ZBH: 119.43 (-2.11), PFE: 34.84 (-0.09), LLY: 74.70 (-0.14), GSK: 42.70 (-0.15), GLPG: 57.40 (-1.60), AXSM: 8.08 (+0.18), OMER: 10.79 (-0.94), CANF: 2.97 (-0.03), AST: 3.17 (-0.04), AKTX: 14.61 (+0.61)
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
Marketwired - Tue Apr 19, 9:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock."
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer.
Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 16.42 (-0.39), TTPH: 4.36 (-0.12), ADRO: 12.24 (-0.25), EBS: 43.85 (-0.37), UTHR: 116.34 (-2.97), BMY: 73.91 (-0.38), PFNX: 7.41 (-0.41), PIP: 2.26 (unch), IBIO: 0.65 (unch), OGEN: 0.68 (+0.09)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.
CELGZ: 1.51 (+0.06)
Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling, Cellceutix and Yahoo Japan
ACCESSWIRE - Wed Mar 09, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ALUF Holdings Inc. (OTC: AHIX), Vantage Drilling Co. (OTC: VTGDF), Cellceutix Corp. (OTC: CTIX) and Yahoo Japan Corp. (OTC: YAHOY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
Marketwired - Tue Mar 08, 12:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital .
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 82.44 (-3.05), IMGN: 5.45 (-0.20), ARQL: 1.80 (-0.03), LLY: 74.70 (-0.14), GSK: 42.70 (-0.15), ONTY: 1.19 (-0.04), MDVN: 59.68 (+0.05), MRK: 57.00 (-0.17), AZN: 29.85 (-0.02), AVEO: 1.05 (-0.03), GALE: 2.02 (-0.09), PBYI: 35.51 (-2.00), NVS: 81.61 (+0.30), KPTI: 9.56 (+0.24), XLRN: 35.76 (-1.29), EXEL: 7.12 (-0.21)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 249.52 (+2.31), AZN: 29.85 (-0.02), CEMP: 19.38 (-0.10), APHB: 1.93 (-0.01), GLPG: 57.40 (-1.60)
Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Marketwired - Mon Jun 06, 6:01AM CDT
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA" in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA. Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Marketwired - Tue May 31, 6:00AM CDT
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed. Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Marketwire Canada - Thu May 26, 6:01AM CDT
BEVERLY, MA--(Marketwired - May 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis. Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Marketwired - Tue May 24, 9:01AM CDT
BEVERLY, MA--(Marketwired - May 24, 2016) -
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
Marketwire Canada - Wed May 11, 8:30AM CDT
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed. Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.22 (-0.07), OCAT: 8.47 (+0.01), ZBH: 119.43 (-2.11), PFE: 34.84 (-0.09), LLY: 74.70 (-0.14), GSK: 42.70 (-0.15), GLPG: 57.40 (-1.60), AXSM: 8.08 (+0.18), OMER: 10.79 (-0.94), CANF: 2.97 (-0.03), AST: 3.17 (-0.04), AKTX: 14.61 (+0.61)
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
Marketwired - Tue Apr 19, 9:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock." Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer. Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 16.42 (-0.39), TTPH: 4.36 (-0.12), ADRO: 12.24 (-0.25), EBS: 43.85 (-0.37), UTHR: 116.34 (-2.97), BMY: 73.91 (-0.38), PFNX: 7.41 (-0.41), PIP: 2.26 (unch), IBIO: 0.65 (unch), OGEN: 0.68 (+0.09)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern. CELGZ: 1.51 (+0.06)
Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling, Cellceutix and Yahoo Japan
ACCESSWIRE - Wed Mar 09, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ALUF Holdings Inc. (OTC: AHIX), Vantage Drilling Co. (OTC: VTGDF), Cellceutix Corp. (OTC: CTIX) and Yahoo Japan Corp. (OTC: YAHOY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
Marketwired - Tue Mar 08, 12:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital . Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 82.44 (-3.05), IMGN: 5.45 (-0.20), ARQL: 1.80 (-0.03), LLY: 74.70 (-0.14), GSK: 42.70 (-0.15), ONTY: 1.19 (-0.04), MDVN: 59.68 (+0.05), MRK: 57.00 (-0.17), AZN: 29.85 (-0.02), AVEO: 1.05 (-0.03), GALE: 2.02 (-0.09), PBYI: 35.51 (-2.00), NVS: 81.61 (+0.30), KPTI: 9.56 (+0.24), XLRN: 35.76 (-1.29), EXEL: 7.12 (-0.21)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 249.52 (+2.31), AZN: 29.85 (-0.02), CEMP: 19.38 (-0.10), APHB: 1.93 (-0.01), GLPG: 57.40 (-1.60)
